Menlo Park, CA, United States of America

Steven E Cwirla

USPTO Granted Patents = 38 (Patent Applications = 13)

Average Co-Inventor Count = 4.3

ph-index = 15

Forward Citations = 2,328(Granted Patents)

Location History:

Palo Alto, CA (US) (1995 - 2009)
Menlo Park, CA (US) (1998 - 2024)

Company Filing History:

Affymax Technologies, N.v.

Smithkline Beecham Corporation

Years Active: 1995-2024

Loading Chart...

38 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 11999771 - IL-7Rαγc ligand immunoglobulin fusion proteins (2024-06-04),

2. 11965015 - IL-7R-α-γ binding compounds (2024-04-23),

3. 11746139 - IL-7Rαγc binding compounds (2023-09-05),

4. 11718654 - IL-2R-βγ binding compounds (2023-08-08),

5. 11692009 - IL-2alpha receptor subunit binding compounds (2023-07-04),

6. 11548914 - IL-2Rgamma binding compounds (2023-01-10),

7. 11358986 - IL-2RBETA binding compounds (2022-06-14),

8. 11254729 - IL-7R-α binding compounds (2022-02-22),

9. 11248030 - Dual IL-2R and IL-7R binding compounds (2022-02-15),

10. 11248025 - IL-2alpha receptor subunit binding compounds (2022-02-15),

11. 10703776 - IL-2RBeta binding compounds (2020-07-07),

12. 10689417 - IL-2Rγ binding compounds (2020-06-23),

13. 8227422 - Peptides and compounds that bind to a receptor (2012-07-24),

14. 7741062 - Epitope-captured antibody display (2010-06-22),

15. 7553617 - Peptide library and screening systems (2009-06-30),

Title: The Innovations of Steven E. Cwirla: A Pioneer in Immunology

Introduction: Steven E. Cwirla, based in Menlo Park, California, has made significant contributions to the field of immunology, holding a remarkable portfolio of 38 patents. His innovative work predominantly focuses on IL-7 receptor (IL-7R) technologies, aiming to develop therapies for various diseases including cancer and autoimmune disorders.

Latest Patents: Cwirla's recent patents revolve around IL-7R agonists, specifically the IL-7Rαγc ligand immunoglobulin fusion proteins. These innovations include the disclosure of IL-7Rαγc ligands and IL-7Rαγc IgG-Fc fusion proteins, which demonstrate potential in enhancing immune responses. Additionally, his work on IL-7R-α-γ binding compounds offers promising solutions for therapeutic applications, highlighting their utility in treating cancer, viral diseases, autoimmune diseases, and inflammatory diseases.

Career Highlights: Throughout his career, Steven E. Cwirla has been instrumental in the advancement of immunological therapies. His expertise has been honed through his roles at leading biotech firms, including Medikine, Inc. and Affymax Technologies N.V., where he has contributed to groundbreaking research and development efforts.

Collaborations: Cwirla has collaborated with notable professionals in his field, including William J. Dower and Ronald W. Barrett. These partnerships have fostered an environment of innovation and discovery, pushing the boundaries of what is possible in the realm of immunotherapeutics.

Conclusion: Steven E. Cwirla continues to make an impact in the scientific community through his innovative patents and collaborations. His dedication to research and development in immunology marks him as a distinguished inventor whose work has the potential to improve the lives of many patients suffering from challenging diseases.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

13 patents pending:

Please report any incorrect information to support@idiyas.com

9 patents pending (EPO):

Please report any incorrect information to support@idiyas.com

Inventor’s Patent Attorneys refers to legal professionals with specialized expertise in representing inventors throughout the patent process. These attorneys assist inventors in navigating the complexities of patent law, including filing patent applications, conducting patent searches, and protecting intellectual property rights. They play a crucial role in helping inventors secure patents for their innovative creations.